FDA grants accelerated approval to dostarlimab for a defined rectal-cancer group — sources for revision 1
U.S. Food and Drug Administration
Source date: 2026-10-19.
Supporting location: FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer; content current October 19.
Source dates are distinct from Iliyn’s preparation date. Source statements do not independently prove underlying events. No full source articles or source photographs are reproduced.